Club Updates

At the invitation of State Treasurer Deb Goldberg, Dr. Earlene Avalon recently moderated a roundtable discussion with healthcare, pharmaceutical and biotech executives on how to increase the gender and racial diversity of boards. Treasurer Goldberg is making this issue front and center as she seeks to leverage the power of PRIM investments to more boldly drive change in the boardroom.

Atinuke Diver served on the faculty at the 2017 Association of Corporate Counsel's Corporate Counsel University in New Orleans. She was co-presenter on a session entitled "Managing Risk and Compliance."

Amy Donovan, a real estate salesperson with LandVest, extends her thanks to two Club members for helping her grow her business. She was referred by member Catherine White to a seller of a Beacon Hill penthouse condominium. Amy's ambassador, Denise Doyle, found her dream home at Boston's Waterfront following a lengthy search with Amy as her buyer's broker. 

Heather Mackey Ford has been elected to the board of the Girl Scouts of Eastern Massachusetts, after finding the opportunity through The Boston Club's Nonprofit Board Committee. Read more about her appointment here!

Emily Klein
, founder and principal of Flexwork Global, was interviewed in a piece featured on OfficeSpace Software Workplace Unplugged.

Harvard Pilgrim Health Care has elected Joyce A. Murphy as chair of its Board of Directors. Joyce is Executive Vice Chancellor of UMass Medical School's Commonwealth Medicine division, and has served on Harvard Pilgrim's board since 2009. Joyce was recommended to then-Harvard Pilgrim CEO Charlie Baker by the Club's Corporate Board Committee. You can read more about Joyce's appointment here.

Enterome SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce that Mary Thistle has joined the Enterome board as a Non-executive Director. Mary brings extensive experience in the life sciences industry, serving in senior finance, operations and business development roles. She is currently Chief Operating Officer at Dimension Therapeutics, Inc., a biopharmaceutical company discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Prior to joining Dimension in 2015, Mary was SVP, Business Development at Cubist Pharmaceuticals, where she was responsible for four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals.